中银国际发表研究报告指，中生制药(01177.HK) 去年度收入按年增长10.2%至289亿元人民币，略低于该行预测，经调整净利润按年增长33.5%至34.6亿元人民币，超出市场预期。年内创新药销售额按年增长21.9%，对总收入贡献从2023年的37.8%提升至41.8%。得益于创新/生物类似药的持续销售势头和仿制药的稳定/正增，管理层预计2025年营收将实现两位数增长。该行维持对中生制药的“买入”评级，目标价上调至4.5元。(gc/u)(港股报价延迟最少十五分钟。沽空资料截至 2025-03-21 12:25。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.